⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742115 | 0.67 | NISCH (0.56) | — | |
| SCHEMBL9575282 | 0.63 | NISCH (0.55) | — | |
| SCHEMBL9575185 | 0.63 | NISCH (0.55) | — | |
| SCHEMBL7349398 | 0.63 | — | — | |
| SCHEMBL4760505 | 0.63 | — | — | |
| SCHEMBL3957418 | 0.62 | — | — | |
| Ethylene Thiourea SCHEMBL137081 | 0.62 | — | — | |
| SCHEMBL2288651 | 0.62 | — | — | |
| SCHEMBL111668 | 0.62 | — | — | |
| SCHEMBL11563018 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549305-B1 | ALPHA 2B 0R 2B/2C ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF MORBUS ALZHEIMER AND MORBUS PARKINSON | ALLERGAN INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1549314-B1 | USE OF BRIMONIDINE IN THE TREATMENT OF DEMENTIA AND PARKINSONS DISEASE | ALLERGAN INC (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1549305-A1 | ALPHA 2B 0R 2B/2C ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATION | Allergan, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1549314-A1 | METHOD OF USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINES IN THE TREATMENT OF DEMENTIA AND PARKINSONS DISEASE | Allergan, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040138312-A1 | Methods for the treatment of neurodegeneration | ALLERGAN, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040116436-A1 | Treatment of dementia and parkinson's disease | ALLERGAN, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004032913-A1 | ALPHA 2B 0R 2B/2C ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATION | ALLERGAN, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004032934-A1 | METHOD OF USING (2-IMIDAZOLIN-2-YLAMINO) QINOXALINES IN THE TREATMENT OF DEMENTIA AND PARKINSONS | ALLERGAN, INC. (US) | 2004-04-22 | — | — | WO | disclosed |